权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Establishment of continuous monitoring method of hemoglobin level using non-invasive instrument

无创仪器连续监测血红蛋白水平方法的建立

基本信息

批准号：
16590458
负责人：
SAIGO Katsuyasu
金额：
$ 2.11万
依托单位：
Kobe University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2004
资助国家：
日本
起止时间：
2004 至 2005
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-16590458/
关键词：
non-invasive detection of hemoglobin Astrim Fragmented red cells Spherocytes Autologous blood storage 日差再現性脂肪乳剤 XE-2100

项目摘要

We evaluated new instrument, Astrim (Sysmex) that can detect hemoglobin level non-invasively, for the purpose of the clinical usage such as continuous monitoring. The effects of biological conditions on hemoglobin detection by Astrim, and possibility of application to autologous blood collection were studied.1.The effects of morphological changes of RBCWe studied about the effects of fragmented red cells (FRC) on hemoglobin detection by Astrim. FRC were produced from washed red cells by heart treatment. There was no affection of FRC on hemoglobin detection in the samples containing FRC in the ratio of up to 18%. O the other hand, hemolytic samples obtained by freezing-thawing method gave us slightly lower data in comparison with those obtained by automatic hematology analyzer. Moreover, spherocytes made in hypotonic solution affected to obtain higher data than true values.2.The effects of clinically available drugThe effects of several drugs that can be used for the patients in severe … More condition were studied. In these drugs, addition of soybean oil, Intrafat^R, resulted in slightly higher data than true valus. However, as only 2g/dL change was observed in the blood sample containing 10% soybean oil, no clinical restriction will be required.3.Development of new detection probe suitable for wristsBecause original Astrim, which use permeable characteristics of near-infrared radiations for middle finger, cannot be applied to severely ill patients, new detection probe suitable for wrists using reflection radiation has been developed.4.Application to pre-evaluation for the patients who undergo autologous blood storageOne hundred and twenty two hemoglobin values before blood collection from 52 patients were evaluated with both Astrim and conventional hematology analyzer. The values obtained by Astrim (NINV-Hb) significantly correlated with those by hematology analyzer (TR-Hb) (r=0.527, p<0.0001). There was no relationship between the ratio of NINV-Hb/TR-Hb and MCV nor RDW. As in the 8 cases the differences of the two method were larger than 2.1, these patients were considered not suitable for Astrim trial. In the remaining 44 cases, 49 second or later blood collection exhibited more than 12g/dL hemoglobin by Astrim. In these cases, all detection with one exception exhibited more than 11g/dL of TR-Hb. It seems to be possible to omit hematological pre-check for these patients. Less

我们评估了新型仪器Astrim（Sysmex），它可以无创地检测血红蛋白水平，用于临床用途，如连续监测。研究了生物学条件对Astrim检测血红蛋白的影响，以及应用于自体血采集的可能性。1.红细胞形态变化的影响研究了碎片红细胞（fragmented red cells，FRC）对Astrim检测血红蛋白的影响。通过心脏处理从洗涤的红细胞产生FRC。在含有FRC的样本中，FRC对血红蛋白检测无影响，其比例高达18%。冻融法溶血标本的检测结果略低于全自动血细胞分析仪。此外，在低渗溶液中制备的球形红细胞影响获得比真实值更高的数据。2.临床可用药物的效果几种药物可用于重度患者的效果 ...更多信息条件进行了研究。在这些药物中，添加大豆油Intrafat^R导致数据略高于真实值。然而，由于在含有10%大豆油的血液样品中仅观察到2g/dL的变化，因此不需要临床限制。3.开发适用于手腕的新检测探头由于原始Astrim利用中指近红外辐射的可渗透特性，不能应用于重症患者，研制了一种适用于腕部的反射辐射式探测探头。对接受自体血液储存的患者的评估52例患者在采血前的122个血红蛋白值进行了评估，Astrim和常规血液分析仪。Astrim（NINV-Hb）与血细胞分析仪（TR-Hb）测定值呈显著相关（r=0.527，p<0.0001）。NINV-Hb/TR-Hb比值与MCV、RDW均无相关性。由于8例患者两种方法的差异大于2.1，因此认为这些患者不适合进行Astrim试验。在其余44例病例中，49秒或更晚的血液采集显示Astrim血红蛋白超过12 g/dL。在这些情况下，除一个例外，所有检测结果均显示TR-Hb超过11 g/dL。似乎可以省略这些患者的血液学预检查。少

项目成果

期刊论文数量（42）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Troglitazone inhibits cell growth and induces apoptosis of B-ALL cells with t(14;18).

Troglitazone 通过 t(14;18) 抑制细胞生长并诱导 B-ALL 细胞凋亡。

DOI：
发表时间：
2006
期刊：
Acta Haematol 116
影响因子：
0
作者：
Takenokuchi M;Saigo K;Nakamachi Y;Kawano S;Hashimoto M;Fujioka T;Koizumi T;Tatsumi E;Kumagai S
通讯作者：
Kumagai S

Excellent results obtained with rituximab combined with a small dose of L-PAM for a refractory follicular lymphoma patient.

利妥昔单抗联合小剂量 L-PAM 对难治性滤泡性淋巴瘤患者取得了优异的效果。